위암 진단 시장 : 전략적 인사이트와 예측(2026-2035년)

The Diagnostics for Gastric Cancer Market is anticipated to grow at a CAGR of 9.6% from USD 4.49 billion in 2026 to USD 10.21 billion in 2035.

The diagnostics for gastric cancer market is experiencing significant transformation driven by the paradigm shift toward biomarker-directed therapies and precision oncology. The market's evolution is characterized by the growing recognition that treatment outcomes depend heavily on accurate molecular characterization rather than histological classification alone. This realization is creating substantial demand for advanced diagnostic solutions capable of identifying key biomarkers including HER2, PD-L1, MSI, and Claudin 18.2. The convergence of endoscopic diagnostics, histopathology, molecular testing, and liquid biopsy technologies is enabling more comprehensive disease characterization and treatment stratification. Healthcare systems are increasingly integrating biomarker evaluation earlier in diagnostic workflows because therapeutic selection depends on molecular evidence. The emergence of targeted therapies and immunotherapies is expanding the range of clinically actionable biomarkers, creating demand for broader testing strategies. Regulatory agencies are strengthening oversight of companion diagnostics, recognizing their critical role in enabling personalized gastric cancer treatment. Diagnostic manufacturers are expanding companion testing portfolios and strengthening evidence-generation activities to support clinical adoption and reimbursement. The market is witnessing significant investment in digital pathology, next-generation sequencing, and liquid biopsy technologies, positioning advanced diagnostics as a cornerstone of gastric cancer management.

Market Drivers

The expansion of biomarker-driven therapy selection represents the primary driver for the gastric cancer diagnostics market. Targeted oncology treatment requires molecular validation because therapeutic efficacy depends on biomarker status. Demand is increasing for HER2, PD-L1, MSI, and Claudin 18.2 testing because physicians must identify eligible patients before treatment initiation. This requirement expands testing volumes across pathology laboratories. Healthcare providers are integrating biomarker evaluation earlier in diagnostic workflows, resulting in stronger demand for gastric cancer diagnostic services. The increasing adoption of precision oncology is further accelerating market growth. Precision oncology depends on comprehensive disease characterization because tumor heterogeneity influences treatment response. Demand is increasing for molecular diagnostics because clinicians seek greater insight into gastric cancer biology. This expectation raises the need for advanced testing technologies. Laboratories are expanding genomic profiling capabilities to support these requirements, resulting in growing utilization of molecular diagnostic platforms. The rising focus on earlier disease detection is driving investment in advanced diagnostic pathways. Clinical outcomes improve when gastric cancer is identified earlier because therapeutic options remain broader during initial stages. Healthcare systems aim to reduce advanced-stage presentation rates, encouraging investment in advanced endoscopic and pathology technologies. Providers are adopting enhanced diagnostic workflows to improve detection rates, increasing demand across the diagnostic ecosystem. The growth of companion diagnostics is supporting targeted treatment utilization. Regulatory approvals increasingly link therapies to biomarker testing, creating collaboration opportunities between diagnostics and therapeutics developers. Diagnostic manufacturers are expanding companion testing portfolios to support commercialization efforts, resulting in sustained market growth.

Market Restraints

High costs associated with molecular testing limit adoption because advanced technologies require specialized infrastructure and expertise. The significant investment needed for sophisticated diagnostic equipment and skilled personnel creates barriers for smaller laboratories and healthcare facilities. Variability in reimbursement policies constrains utilization because payer coverage differs across healthcare systems and geographic regions. Inconsistent coverage frameworks create uncertainty for diagnostic providers and limit patient access to advanced testing options. Limited access to specialized pathology services restricts testing availability because trained personnel and advanced laboratories remain concentrated in selected regions. The shortage of molecular pathology expertise in many healthcare systems limits the scalability of biomarker testing programs. Regulatory complexities across different jurisdictions create compliance burdens for diagnostic manufacturers seeking to commercialize new testing solutions. The evolving regulatory landscape requires continuous adaptation, increasing operational costs and time-to-market for new products.

Technology and Segment Insights

The technology landscape is characterized by the growing importance of integrated diagnostic platforms. Demand is shifting toward broader testing strategies because multiple biomarkers now influence treatment pathways. This expansion increases laboratory complexity and data interpretation requirements. IHC and FISH technologies remain fundamental because established biomarkers continue guiding treatment decisions. PCR and NGS platforms are expanding for broader molecular assessment because clinicians seek comprehensive genomic characterization. Digital pathology adoption is expanding because laboratories require scalable interpretation workflows. Liquid biopsy technologies are gaining attention because clinicians seek minimally invasive monitoring approaches. The segment analysis reveals that molecular diagnostics represent a major growth area because biomarker-directed therapies require more than conventional histopathological evaluation. HER2 testing demand is increasing because HER2-targeted therapies require validated biomarker identification. PD-L1 and MSI testing utilization is expanding as immunotherapy adoption grows. Claudin 18.2 testing is gaining relevance because emerging targeted therapies depend on patient stratification. Endoscopic diagnostics remain essential for initial disease detection and tissue acquisition. Histopathology diagnostics provide the foundational tissue evaluation that supports biomarker testing. Diagnostic laboratories and cancer centers represent key end-user segments, with hospitals playing a central role in integrated diagnostic workflows. The integration of artificial intelligence is becoming increasingly important because diagnostic workloads and molecular complexity continue expanding simultaneously. AI-enabled pathology and biomarker interpretation tools are improving efficiency and consistency in diagnostic workflows.

Competitive and Strategic Outlook

The competitive landscape features established diagnostic companies with broad oncology portfolios alongside specialized molecular testing providers. F. Hoffmann-La Roche maintains a strong position because it combines a leading oncology therapeutics portfolio with one of the most established companion diagnostics businesses. The company's integration of diagnostic and therapeutic capabilities creates a competitive advantage in biomarker-guided treatment selection. Agilent Technologies remains strategically distinct because its Dako pathology portfolio supports many biomarker testing workflows used in precision oncology, with strong positioning within tissue-based gastric cancer diagnostics. QIAGEN combines molecular testing expertise with extensive experience in companion diagnostic development, expanding partnerships with pharmaceutical developers. Abbott Laboratories possesses broad diagnostic capabilities spanning molecular testing, laboratory systems, and clinical diagnostics, with sustained participation in cancer diagnostics markets. Thermo Fisher Scientific provides a comprehensive portfolio of sequencing platforms, molecular diagnostic technologies, reagents, and laboratory workflow solutions, with strong positioning across multiple layers of the gastric cancer diagnostics value chain. Illumina's sequencing technologies serve as a foundation for many genomic profiling applications, with continued influence over the expansion of molecular diagnostics. Companies are pursuing product portfolio expansion through innovation in molecular assays, digital pathology solutions, and liquid biopsy technologies. Strategic collaborations between diagnostic manufacturers and pharmaceutical companies are increasing, driven by the need for companion diagnostic development alongside targeted therapies. Geographic expansion remains a key strategic priority, with companies targeting rapidly growing emerging markets, particularly in Asia Pacific where gastric cancer incidence remains high. Mergers and acquisitions are occurring as larger players seek to expand market presence and technology portfolios. Diagnostic companies are investing in clinical validation programs and real-world evidence generation to support reimbursement and adoption.

Short Conclusion

The diagnostics for gastric cancer market is positioned for sustained growth driven by the convergence of biomarker-driven therapy, precision oncology, and expanding healthcare infrastructure. The transition toward integrated diagnostic platforms that combine histopathology, molecular testing, and digital solutions represents a fundamental shift in gastric cancer management. While challenges related to high costs, reimbursement variability, and limited specialized expertise persist, strategic investments in technology, evidence generation, and regulatory compliance are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with gastric cancer diagnostics evolving into foundational tools that determine therapeutic access, treatment response, and long-term patient outcomes across the continuum of care.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Diagnostics for Gastric Cancer Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Gastric Cancer Diagnostics Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast Analysis (2026-2035)
• 3.7 Gastric Cancer Disease Burden Analysis
• 3.8 Gastric Cancer Prevalence Analysis
• 3.9 Diagnosed Patient Population Analysis
• 3.10 Gastric Cancer Testing Volume Analysis
• 3.11 Patient Journey Analysis in Gastric Cancer Diagnosis
• 3.12 Biomarker Testing Trends in Gastric Cancer
• 3.13 HER2, PD-L1, MSI, and Claudin 18.2 Testing Landscape

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies in Gastric Cancer Diagnostics
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 Technology Roadmap
• 6.6 AI Integration in Gastric Cancer Diagnostics
• 6.7 Digital Pathology Integration

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Diagnostics for Gastric Cancer Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Biomarker Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology

9. Diagnostics for Gastric Cancer Market Segment Analysis (2021-2035)

• 9.1 By Diagnostic Type
  • 9.1.1 Endoscopic Diagnostics
  • 9.1.2 Histopathology Diagnostics
  • 9.1.3 Molecular Diagnostics
  • 9.1.4 Immunohistochemistry (IHC)-Based Diagnostics
  • 9.1.5 In Situ Hybridization (ISH)-Based Diagnostics
  • 9.1.6 Liquid Biopsy Diagnostics
• 9.2 By Biomarker Type
  • 9.2.1 HER2 Biomarker Testing
  • 9.2.2 PD-L1 Biomarker Testing
  • 9.2.3 Microsatellite Instability (MSI) Testing
  • 9.2.4 Claudin 18.2 Testing
  • 9.2.5 Epstein-Barr Virus (EBV) Testing
  • 9.2.6 Other Biomarker Testing
• 9.3 By Technology
  • 9.3.1 Immunohistochemistry (IHC)
  • 9.3.2 Fluorescence In Situ Hybridization (FISH)
  • 9.3.3 Polymerase Chain Reaction (PCR)
  • 9.3.4 Next-Generation Sequencing (NGS)
  • 9.3.5 Digital Pathology
  • 9.3.6 Liquid Biopsy Technologies
• 9.4 By Sample Type
  • 9.4.1 Tissue Biopsy
  • 9.4.2 Blood Samples
  • 9.4.3 Gastric Fluid Samples
  • 9.4.4 Other Biological Samples
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Diagnostic Laboratories
  • 9.5.3 Cancer Centers
  • 9.5.4 Academic and Research Institutes

10. Diagnostics for Gastric Cancer Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Diagnostics for Gastric Cancer Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 South Korea
• 11.11 India
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche
• 13.2 Agilent Technologies
• 13.3 QIAGEN
• 13.4 Abbott Laboratories
• 13.5 Thermo Fisher Scientific
• 13.6 Illumina
• 13.7 Sysmex Corporation
• 13.8 Danaher Corporation
• 13.9 Guardant Health
• 13.10 Foundation Medicine
• 13.11 Exact Sciences
• 13.12 NeoGenomics
• 13.13 Bio-Rad Laboratories
• 13.14 Leica Biosystems
• 13.15 Tempus AI

14. Diagnostics for Gastric Cancer Market Commercial Forecast Analysis

• 14.1 HER2 Diagnostic Testing Forecast
• 14.2 PD-L1 Diagnostic Testing Forecast
• 14.3 MSI Diagnostic Testing Forecast
• 14.4 Endoscopic Diagnostic Procedures Forecast
• 14.5 Histopathology Diagnostic Testing Forecast
• 14.6 Molecular Diagnostic Testing Forecast
• 14.7 Liquid Biopsy Diagnostic Testing Forecast

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends